skip to main content

    Updated Visitor Guidelines

 

MENU

 

Spring Trainee Research Symposium

2020 VIRTUAL Spring Symposium: Friday, June 26

Howard Crawford, PhD

Out of concern for the health and safety of our research community we are offering a modified virtual symposium featuring updates from the Office of Education and Training and a Keynote Address in place of our 2020 Spring Trainee Research Symposium

Cancer Center Members

This page has moved / been renamed Rogel Cancer Center Members. Please update your bookmarks to the new URL.

Half of Breast Cancer Patients Get Genetic Counseling

As new genes are linked to breast cancer occurring in families, and as genetic testing becomes more important in directing treatment for newly diagnosed patients, a substantial number of those at the highest risk are not getting tested.

With $150M gift, Rogels will help U-M Cancer Center transform cancer research, care

Richard and Susan Rogel are on a mission to boost innovative cancer research and develop the next generation of cancer pioneers -- and they are committing $150 million to the University of Michigan Comprehensive Cancer Center to realize that vision.

Leadership

Eric Fearon, M.D., Ph.D.

Eric R. Fearon, M.D., Ph.D.
Emanuel N Maisel Professor of Oncology
Director, University of Michigan Rogel Cancer Center
Associate Dean for Cancer Programs, University of Michigan Medical School

HPV specialist Diane Harper to lead community outreach efforts at the Cancer Center

Diane Harper, M.D., MPH, M.S., professor of family medicine at Michigan Medicine, has been named physician director for Community Outreach, Engagement and Health Disparities at the University of Michigan Rogel Cancer Center. She will lead the establishment of a community outreach engagement committee to build relationships with the community and seek input from community leaders.

Triple-Negative Breast Cancer

Triple-negative breast cancer cells do not express three primary markers – estrogen receptor, progesterone receptor, and HER2 receptor - that are known to play a role in breast cancer. Approximately 10% to 20% of breast cancers are triple-negative.

Events for Members

The following events are intended specifically for Rogel Cancer Center members.

 

View fewer options: National Conferences    |     Rogel Trainees    |     Patient / Family Events

How Immune Cells Could Guide Head and Neck Cancer Treatment Decisions

For patients with head and neck cancer, responses to treatment vary. Some do well with a combination of chemotherapy and radiation. Others have better outcomes with surgery. The question for clinicians is how to make the right choice before treatment. New evidence suggests a patient’s immune system may be a deciding factor.

Pages